grid laser treatment was performed in both eyes seven months ago . in spite of seven months of follow - up after grid laser with good systemic control ,
persistent csme was found in both the eyes with central macular thickness ( cmt ) of 311 m and 452 m in the right and left eye respectively [ figs .
intravitreal bevacizumab was given in the left eye and the right eye was kept under observation .
four weeks after bevacizumab injection , cmt was reduced to 355 m in the left eye with persistent csme observed with maximum macular thickness ( mmt ) of 461 m [ fig .
intravitreal dexamethasone implant was injected in the right eye whereas second bevacizumab injection was given in the left eye . at six weeks of follow - up
1e ] whereas cmt and mmt were 306 m and 420 m respectively in the left eye [ fig .
persistent macular edema ( me ) in the right eye after 7 months follow - up of grid laser with central macular thickness ( cmt ) 311m . intervention - none .
( b ) persistent me in the left eye after 7 months of grid laser .
( c ) right eye macular sd - oct after 4 weeks of follow - up ( me worsened and cmt increased to 350 m ) .
( d ) left eye macular sd - oct after 4 weeks of 1st intravitreal avastin ( me improved and cmt and mmt reduced to 355 m and 461 m respectively ) .
( e ) right eye macular sd - oct after 6 weeks of implant ( me subsided and cmt became 261m ) .
( f ) left eye macular sd - oct after 6 weeks of 2nd intravitreal bevacizumab .
persistent me with cmt 306 m and mmt 420 m ( sd - oct - spectral domain optical coherence tomography ) high intraocular pressure was recorded in the right eye ( 26 mmhg ) and patient was kept on antiglaucoma medications .
in the present case , dexamethasone sustained - release implant was able to successfully bring down the cmt to the normal level in refractory csme within six weeks whereas persistent csme was observed even after using two bevacizumab injections in the other eye .
as this is a single case with a very short follow - up , it is very difficult to comment on the efficacy of dexamethasone implant per se but comparison with fellow eye ( bevacizumab ) in similar systemic metabolic conditions makes it an interesting observation even at short term .
it is important to evaluate the efficacy of dexamethasone sustained - release implant for the long term because that will give a clue towards its cost - effectiveness compared to the existing therapies .
it should not be concluded with this report that dexamethasone sustained - release implant is a better therapeutic option than bevacizumab because there was difference in the nature of macular edema in both the eyes i.e. right eye had early edema in comparison to left eye and both the therapies caused reduction in the macular thickness .
recent results of resolve and read 2 study have shown successful use of ranibizumab in cases of dme . as far as the frequency of ranibizumab
is concerned , the read 2 study has shown reduction in the frequency of ranibizumab injection to 2.9 when it is combined with laser , compared to 5.3 and 4.4 in ranibizumab and laser alone patients respectively during 18 months of follow - up .
future comparative clinical studies with a large sample size and long - term follow - up after fda approval of dexamethasone sustained - release implant for dme will be able to provide better results and guidelines .
 we report on the significant improvement of central macular thickness in a case of clinically significant macular edema after dexamethasone 0.7 mg sustained - release intravitreal implant ( ozurdex ; allergan , inc , irvine , ca , usa ) . 
 patient presented to us with persistent clinically significant macular edema ( csme ) in both eyes . 
 right eye received dexamethasone implant and left eye received two intravitreal bevacizumab injections 1.25 mg/0.05 ml ( avastin ; genentech inc . , south san francisco , ca , usa ) with an interval of four weeks . 
 after six weeks of follow - up , dexamethasone implant in the right eye showed normal macular thickness whereas persistent macular edema ( me ) was found even after second intravitreal bevacizumab injection in the left eye . 
Case Report
Discussion